State Street’s Kyverna Therapeutics KYTX Stock Holding History

State Street’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.19M	Buy	138,300 +47,000	+51%	+$392K	﹤0.01%	3450
2025 Q4	$858K	Hold	91,300	–	–	﹤0.01%	3557
2025 Q3	$548K	Hold	91,300	–	–	﹤0.01%	3644
2025 Q2	$280K	Sell	91,300 -283,278	-76%	-$701K	﹤0.01%	3745
2025 Q1	$723K	Sell	374,578 -5,310	-1%	-$15.7K	﹤0.01%	3507
2024 Q4	$1.42M	Buy	379,888 +53,696	+16%	+$257K	﹤0.01%	3411
2024 Q3	$1.6M	Buy	326,192 +10,244	+3%	+$79K	﹤0.01%	3393
2024 Q2	$2.37M	Buy	315,948 +265,548	+527%	+$4.06M	﹤0.01%	3256
2024 Q1	$1.25M	Buy	+50,400	New	+$1.41M	﹤0.01%	3410

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

State Street's KYTX Position: Q1 2026 in Review

State Street increased its Kyverna Therapeutics (KYTX) stake by 51% in Q1 2026, buying an estimated $392K and bringing the position to 138,300 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #3450.

State Street first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.37M in Q2 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

State Street held 138,300 shares of Kyverna Therapeutics worth $1.19M as of Q1 2026.
State Street bought 47,000 Kyverna Therapeutics shares in Q1 2026, an estimated $392K.
Kyverna Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3450 holding.
State Street first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
State Street's Kyverna Therapeutics position peaked at $2.37M in Q2 2024.
111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.